Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

Open access

Abstract

Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the identification of AD pathology or monitoring of disease progression. Blood biomarkers that correlate with changes in cognition and atrophy during the course of the disease could be used in clinical trials to identify successful interventions and thereby accelerate the development of efficient therapies. When disease-modifying treatments become approved for use, efficient blood-based biomarkers might also inform on treatment implementation and management in clinical practice. In the BioFINDER-1 cohort, plasma phosphorylated (p)-tau231 and amyloid-β42/40 ratio were more changed at lower thresholds of amyloid pathology. Longitudinally, however, only p-tau217 demonstrated marked amyloid-dependent changes over 4–6 years in both preclinical and symptomatic stages of the disease, with no such changes observed in p-tau231, p-tau181, amyloid-β42/40, glial acidic fibrillary protein or neurofilament light. Only longitudinal increases of p-tau217 were also associated with clinical deterioration and brain atrophy in preclinical AD. The selective longitudinal increase of p-tau217 and its associations with cognitive decline and atrophy was confirmed in an independent cohort (Wisconsin Registry for Alzheimer’s Prevention). These findings support the differential association of plasma biomarkers with disease development and strongly highlight p-tau217 as a surrogate marker of disease progression in preclinical and prodromal AD, with impact for the development of new disease-modifying treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02074-w

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Associations between plasma biomarkers and Aβ-PET in BioFINDER-1 (cohort 1). Log10-transformed plasma biomarker levels were compared between the centiloid (CL) groups, <12 (MD −2.6; n = 139; reference group), Q1 (range 12.0–35.9; MD 17.9; n = 27), Q2 (range 35.9–71.7; MD 50.1; n = 24), Q3 (range 71.7–95.3; MD 80.6; n = 25) and Q4 (>95.3; MD 114.1; n = 25) using univariate general linear models adjusting for age. Untransformed data are presented in the boxplots to aid interpretation of biomarker values across different comparisons. One NfL outlier is not shown but was included in the statistical analysis. Boxes show interquartile range, the horizontal lines are medians and the whiskers were plotted using the Tukey method. Two-sided P values were corrected for multiple comparisons using Benjamini–Hochberg FDR; uncorrected and corrected P values are shown in Extended Data Table 6.
Fig. 1 Associations between plasma biomarkers and Aβ-PET in BioFINDER-1 (cohort 1). Log10-transformed plasma biomarker levels were compared between the centiloid (CL) groups, <12 (MD −2.6; n = 139; reference group), Q1 (range 12.0–35.9; MD 17.9; n = 27), Q2 (range 35.9–71.7; MD 50.1; n = 24), Q3 (range 71.7–95.3; MD 80.6; n = 25) and Q4 (>95.3; MD 114.1; n = 25) using univariate general linear models adjusting for age. Untransformed data are presented in the boxplots to aid interpretation of biomarker values across different comparisons. One NfL outlier is not shown but was included in the statistical analysis. Boxes show interquartile range, the horizontal lines are medians and the whiskers were plotted using the Tukey method. Two-sided P values were corrected for multiple comparisons using Benjamini–Hochberg FDR; uncorrected and corrected P values are shown in Extended Data Table 6.CC BY · PubMed Central
Fig. 2 Longitudinal plasma biomarker changes in BioFINDER-1 (cohort 2). a,b, Longitudinal plasma biomarker changes stratified by β-amyloid status (negative, purple; positive, blue) in CU (a) and MCI (b). The x axis shows time from first plasma biomarker sample. Shaded areas represent 95% confidence intervals of the regression lines plotted from linear mixed effects models with the interaction between time and Aβ status as well as baseline Aβ status as independent variables and adjusting for age and sex. All p-tau biomarkers and Aβ42/40 were significantly changed in Aβ+ individuals at baseline in both CU and MCI (P < 0.001). Two-sided P values were corrected for multiple comparisons using Benjamini–Hochberg FDR; corrected and uncorrected P values are shown in Table 1 and Supplementary Table 1. Several outliers (p-tau231, n = 1; p-tau217, n = 9; p-tau181, n = 5; GFAP, n = 4; NfL, n = 4) are not shown but these data were included in the statistical analysis.
Fig. 2 Longitudinal plasma biomarker changes in BioFINDER-1 (cohort 2). a,b, Longitudinal plasma biomarker changes stratified by β-amyloid status (negative, purple; positive, blue) in CU (a) and MCI (b). The x axis shows time from first plasma biomarker sample. Shaded areas represent 95% confidence intervals of the regression lines plotted from linear mixed effects models with the interaction between time and Aβ status as well as baseline Aβ status as independent variables and adjusting for age and sex. All p-tau biomarkers and Aβ42/40 were significantly changed in Aβ+ individuals at baseline in both CU and MCI (P < 0.001). Two-sided P values were corrected for multiple comparisons using Benjamini–Hochberg FDR; corrected and uncorrected P values are shown in Table 1 and Supplementary Table 1. Several outliers (p-tau231, n = 1; p-tau217, n = 9; p-tau181, n = 5; GFAP, n = 4; NfL, n = 4) are not shown but these data were included in the statistical analysis.CC BY · PubMed Central
Fig. 3 Associations of longitudinal plasma biomarkers with longitudinal cognitive decline and brain atrophy in BioFINDER-1 (cohort 2). a–c, The association between longitudinal plasma biomarkers and MMSE (a), mPACC (b) and cortical thickness of the typical AD signature regions (c) in Aβ positive cognitively unimpaired participants. The x axis shows time from first plasma biomarker samples. The model trajectories, shown as the mean slope and the mean ± 2 SD with 95% CI (shaded area), were plotted from linear mixed effects models with the interaction between time and standardized plasma biomarker slopes (derived from subject-level linear regression models) as an independent variable adjusting for age and sex; associations with cognition were also adjusted for years of education. Two-sided P values were corrected for multiple comparisons using Benjamini–Hochberg FDR; corrected and uncorrected P values are shown in Table 2 and Supplementary Table 2.
Fig. 3 Associations of longitudinal plasma biomarkers with longitudinal cognitive decline and brain atrophy in BioFINDER-1 (cohort 2). a–c, The association between longitudinal plasma biomarkers and MMSE (a), mPACC (b) and cortical thickness of the typical AD signature regions (c) in Aβ positive cognitively unimpaired participants. The x axis shows time from first plasma biomarker samples. The model trajectories, shown as the mean slope and the mean ± 2 SD with 95% CI (shaded area), were plotted from linear mixed effects models with the interaction between time and standardized plasma biomarker slopes (derived from subject-level linear regression models) as an independent variable adjusting for age and sex; associations with cognition were also adjusted for years of education. Two-sided P values were corrected for multiple comparisons using Benjamini–Hochberg FDR; corrected and uncorrected P values are shown in Table 2 and Supplementary Table 2.CC BY · PubMed Central
Fig. 4 Longitudinal plasma biomarker changes and their association with cognitive decline in WRAP (cohort 3). a, Longitudinal plasma biomarker change stratified by Aβ status (negative, purple; positive, blue) in CU participants. The average regression lines with 95% CI (shaded area) were plotted from linear mixed effects models with the interaction between time and Aβ status as well as baseline Aβ status independent variables and adjusting for age and sex. All p-tau biomarkers, Aβ42/40 (P < 0.001) and GFAP (P = 0.005) were significantly changed in Aβ+ individuals at baseline. Several outliers (p-tau217, n = 5; p-tau181, n = 2; GFAP, n = 1; NfL, n = 3) are not shown in (a) but these data were included in the statistical analysis. b,c, The association between longitudinal plasma biomarkers and MMSE (b) and mPACC (c) in Aβ-positive cognitively unimpaired participants. The model trajectories, shown as the mean slope and the mean ± 2 SD with 95% CI (shaded area), were plotted from linear mixed effects models with the interaction between time and standardized plasma biomarker slopes (derived from subject-level linear regression models) as an independent variable adjusting for age, sex and years of education. Two-sided P values were corrected for multiple comparisons using Benjamini–Hochberg FDR; corrected and uncorrected P values are shown in Tables 1 and 2 and Supplementary Tables 1 and 2. One outlier with MMSE value of 17 is not shown in b but was included in the statistical analysis The x axes in a–c show time from first plasma biomarker samples.
Fig. 4 Longitudinal plasma biomarker changes and their association with cognitive decline in WRAP (cohort 3). a, Longitudinal plasma biomarker change stratified by Aβ status (negative, purple; positive, blue) in CU participants. The average regression lines with 95% CI (shaded area) were plotted from linear mixed effects models with the interaction between time and Aβ status as well as baseline Aβ status independent variables and adjusting for age and sex. All p-tau biomarkers, Aβ42/40 (P < 0.001) and GFAP (P = 0.005) were significantly changed in Aβ+ individuals at baseline. Several outliers (p-tau217, n = 5; p-tau181, n = 2; GFAP, n = 1; NfL, n = 3) are not shown in (a) but these data were included in the statistical analysis. b,c, The association between longitudinal plasma biomarkers and MMSE (b) and mPACC (c) in Aβ-positive cognitively unimpaired participants. The model trajectories, shown as the mean slope and the mean ± 2 SD with 95% CI (shaded area), were plotted from linear mixed effects models with the interaction between time and standardized plasma biomarker slopes (derived from subject-level linear regression models) as an independent variable adjusting for age, sex and years of education. Two-sided P values were corrected for multiple comparisons using Benjamini–Hochberg FDR; corrected and uncorrected P values are shown in Tables 1 and 2 and Supplementary Tables 1 and 2. One outlier with MMSE value of 17 is not shown in b but was included in the statistical analysis The x axes in a–c show time from first plasma biomarker samples.CC BY · PubMed Central
Extended Data Fig. 1 Associations between plasma biomarkers and CSF Aβ42/40 in BioFINDER-1 (cohort 1). Log10-transformed plasma biomarker levels were compared between the CSF Aβ42/40 quintile groups, Q1 ( > 0.102; median [MD], 0.108; n = 115, reference group), Q2 (range, 0.089-0.102; MD, 0.097; n = 115), Q3 (range 0.064-0.089; MD, 0.079; n = 115), Q4 (range, 0.042-0.064; MD, 0.051; n = 115) and Q5 (range, <0.042; MD, 0.035; n = 115) using univariate general linear models adjusting for age. Untransformed data are presented in the boxplots to aid interpretation of biomarker values across different comparisons. Outliers (p-tau217, n = 1; p-tau181, n = 2; GFAP, n = 1; NfL, n = 2) are not shown in the boxplots but were included in the statistical analysis. Boxes show interquartile range, the horizontal lines are medians, and the whiskers were plotted using Tukey method. Two-sided p-values were corrected for multiple comparisons using Benjamini–Hochberg false discovery rate; uncorrected and corrected p-values are shown in Extended Data Table 6.
Extended Data Fig. 1 Associations between plasma biomarkers and CSF Aβ42/40 in BioFINDER-1 (cohort 1). Log10-transformed plasma biomarker levels were compared between the CSF Aβ42/40 quintile groups, Q1 ( > 0.102; median [MD], 0.108; n = 115, reference group), Q2 (range, 0.089-0.102; MD, 0.097; n = 115), Q3 (range 0.064-0.089; MD, 0.079; n = 115), Q4 (range, 0.042-0.064; MD, 0.051; n = 115) and Q5 (range, <0.042; MD, 0.035; n = 115) using univariate general linear models adjusting for age. Untransformed data are presented in the boxplots to aid interpretation of biomarker values across different comparisons. Outliers (p-tau217, n = 1; p-tau181, n = 2; GFAP, n = 1; NfL, n = 2) are not shown in the boxplots but were included in the statistical analysis. Boxes show interquartile range, the horizontal lines are medians, and the whiskers were plotted using Tukey method. Two-sided p-values were corrected for multiple comparisons using Benjamini–Hochberg false discovery rate; uncorrected and corrected p-values are shown in Extended Data Table 6.CC BY · PubMed Central
Extended Data Fig. 2 Associations between longitudinal plasma biomarkers and brain atrophy in WRAP (cohort 3). The association between longitudinal plasma biomarkers and cortical thickness of the typical AD signature regions in Aβ positive cognitively unimpaired participants. The x-axis show time from first plasma biomarker samples. The model trajectories, shown as the mean slope and the mean±2 SD with 95% CI (shaded area), were plotted from linear mixed effects models with the interaction between time and standardized plasma biomarker slopes (derived from subject-level linear regression models) as the independent variable adjusting for age and sex. Two-sided p-values were corrected for multiple comparisons using Benjamini–Hochberg false discovery rate; corrected and uncorrected p-values are shown in Table 2 and Supplementary Table 2.
Extended Data Fig. 2 Associations between longitudinal plasma biomarkers and brain atrophy in WRAP (cohort 3). The association between longitudinal plasma biomarkers and cortical thickness of the typical AD signature regions in Aβ positive cognitively unimpaired participants. The x-axis show time from first plasma biomarker samples. The model trajectories, shown as the mean slope and the mean±2 SD with 95% CI (shaded area), were plotted from linear mixed effects models with the interaction between time and standardized plasma biomarker slopes (derived from subject-level linear regression models) as the independent variable adjusting for age and sex. Two-sided p-values were corrected for multiple comparisons using Benjamini–Hochberg false discovery rate; corrected and uncorrected p-values are shown in Table 2 and Supplementary Table 2.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 467

Metadata

Authors
Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., Jonaitis, E. M., Koscik, R. L., Cody, K., Betthauser, T. J., Li, Y., Vanmechelen, E., Palmqvist, S., Stomrud, E., Bateman, R. J., Zetterberg, H., Johnson, S. C., Blennow, K., & Hansson, O.
Affiliations
  • King's College London (GB)
  • Lund University (SE)
  • Universidade Federal do Rio Grande do Sul (BR)
  • University of Pittsburgh (US)
  • University of Gothenburg (SE)
  • University of Wisconsin–Madison (US)
  • Washington University in St. Louis (US)
  • ADx NeuroSciences (BE)
  • Sahlgrenska University Hospital (SE)
Corresponding author
  • Blennow, Kaj
  • Hansson, Oskar
Venue
Nature Medicine
Published
2022-12
Volume
28
Issue
12
Pages
2555-2562
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4310603866
Cited by
436
References
53
Citations by year
2026: 99 · 2025: 128 · 2024: 135 · 2023: 72 · 2022: 1
FWCI
52.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Alzheimer's Association (ADSF-21-831377-C, ZEN-21-848495, ADSF‐21‐831376‐C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, #ADSF-21-831381-C, 2021 Zenith Award, -21- 831377-C)
  • Alzheimer's Drug Discovery Foundation (201809–2016862, 201809-2016615, #RDAPB‐201809‐2016615)
  • Eli Lilly and Company
  • Pfizer
  • Biogen
  • Familjen Erling-Perssons Stiftelse (FO2019-0228, 860197)
  • Stiftelsen för Gamla Tjänarinnor (860197, FO2019‐0228)
  • EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
  • Prothena
  • Australian Government
  • Cerveau Technologies
  • European Commission (HORIZON2020, JPND2019‐466‐236, 860197)
  • Lunds Universitet
  • Eisai
  • Hjärnfonden (FO2019-0029, ALZ2022-0006), FO2021-0293, FO2017‑0243, FO2017, ALFGBG-715986, FO2020‐0271, FO2019‐0228, #ALFGBG-965240, JPND2019-466-236)
  • Knut och Alice Wallenbergs Stiftelse (681712, 2017‐0383)
  • Vetenskapsrådet (ALFGBG-965240, ALZ2022-0006, 2017-00915, 2016-00906, (#ALFGBG-715986, 681712, FO2021-0293, 2018-, JPND2019-466-236, 2018-02052, 2021-02219, 2017-00383, FO2017-0243, 2018-02532)
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028, 2020-0314, FO2017-0243)
  • Region Skåne
  • Skånes universitetssjukhus (2020-O000028)
  • Siemens Healthineers
  • Marcus och Amalia Wallenbergs minnesfond (2015.0125)
  • Julius Clinical
  • UK Dementia Research Institute (#2017-00915)
  • Olav Thon Stiftelsen (#FO2019-0228)
  • Stiftelsen Bundy Academy
  • National Institutes of Health (ZEN-21- 848495, AG027161)
  • Genentech
  • Parkinsonfonden (1280/20)
  • Avid Radiopharmaceuticals
  • National Institute on Aging (R01AG068398, RF1AG027161, R01AG021155, R01AG027161, P30AG062715)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
Alzheimer's disease, blood biomarkers, phosphorylated tau217, preclinical Alzheimer's disease, prodromal Alzheimer's disease, disease progression, brain atrophy, cognitive decline, disease-modifying therapy, clinical trial selection, neurofilament light chain, Wisconsin Registry for Alzheimer's Prevention
MeSH terms
Alzheimer Disease, Atrophy, Humans, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. https://app.cochat.ai/papers/10.1038/s41591-022-02074-w
The paper
Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., Jonaitis, E. M., Koscik, R. L., Cody, K., Betthauser, T. J., Li, Y., Vanmechelen, E., Palmqvist, S., Stomrud, E., Bateman, R. J., . . . Hansson, O. (2022). Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nature Medicine. https://doi.org/10.1038/s41591-022-02074-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.